NCT04119024 2026-03-17
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Phase 1 Recruiting
Clinical Trials
43 trialsNCT00107289 2026-03-13
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT03946527 2026-03-02
LAMPARA
Columbia University
Phase 2 Active not recruiting
NCT05636540 2026-02-27
In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Recruiting
NCT01850888 2025-12-18
MIBG for Refractory Neuroblastoma and Pheochromocytoma
Masonic Cancer Center, University of Minnesota
Phase NA Completed
NCT03541720 2025-12-03
18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
St. Jude Children's Research Hospital
Phase EARLY_PHASE1 Active not recruiting
NCT07167329 2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2 Recruiting
NCT06683846 2025-08-24
Ivonescimab in the Treatment of Multiple Advanced Tumors
Fudan University
Phase 2 Recruiting
NCT06377033 2025-07-20
Using the EHR to Advance Genomic Medicine Across a Diverse Health System
University of Pennsylvania
Phase NA Recruiting
NCT04400474 2025-06-19
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT05702944 2025-06-12
The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma
Seoul National University Hospital
Phase 4 Recruiting
NCT05944237 2025-06-08
HTL0039732 in Participants With Advanced Solid Tumours
Cancer Research UK
Phase 1/2 Recruiting
NCT06607692 2024-10-21
LUPARPED
Fundación de investigación HM
Phase 2 Recruiting
NCT01379898 2024-09-19
PRESCRIPT
University Medical Center Groningen
Phase 4 Completed
NCT00655655 2024-08-21
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Phase 1 Completed
NCT06045260 2024-08-13
LUFOR
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Recruiting
NCT04605848 2024-05-09
MICROBAT
University of Avignon
Phase NA Terminated
NCT05069220 2024-03-01
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Recruiting
NCT03008369 2024-02-20
Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
Mayo Clinic
Phase 2 Completed
NCT03176693 2023-11-20
Preoperative Alpha Blockade for Pheochromocytoma
University of California, Los Angeles
Phase 3 Completed
NCT06037135 2023-10-06
Dexmedetomidine Infusion During Laparoscopic Adrenalectomy
Yonsei University
Phase NA Completed
NCT03986593 2023-07-05
Cryoablation of Bone Metastases From Endocrine Tumors
Instituto do Cancer do Estado de São Paulo
Phase NA Terminated
NCT05885399 2023-06-02
The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05885386 2023-06-01
A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05883085 2023-05-31
A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL
Peking Union Medical College Hospital
Phase 2 Unknown
NCT02186678 2023-04-06
DOTATATE
Assistance Publique Hopitaux De Marseille
Phase NA Completed
NCT00442533 2023-04-03
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Radio Isotope Therapy of America
Phase 2/3 Completed
NCT04276597 2023-03-10
PUTNET
Excel Diagnostics and Nuclear Oncology Center
Phase 2 Withdrawn
NCT05133349 2021-11-24
EASOAIPPGL
Nanjing First Hospital, Nanjing Medical University
Phase 2 Unknown
NCT04320589 2021-09-01
the Effect of Dexmedetomidine and Magnesium Sulfate in Open Resection of Pheochromocytoma
National Cancer Institute, Egypt
Phase 2 Completed
NCT03923257 2021-06-08
Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents
University of Iowa
Phase 1/2 Withdrawn
NCT04106843 2020-09-07
Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02672020 2019-09-24
COMETETACTIC
Assistance Publique - Hôpitaux de Paris
Phase NA Completed
NCT01413503 2018-09-18
A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
University of California, San Francisco
Phase 2 Completed
NCT01676025 2017-10-06
PRA
Seoul National University Hospital
Phase NA Completed
NCT02831179 2017-09-28
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn
NCT02618694 2017-03-03
PostLapAdrnl
Suez Canal University
Phase NA Completed
NCT00869050 2016-07-25
Capecitabine and Temozolomide for Neuroendocrine Cancers
Columbia University
Phase 2 Completed
NCT00049023 2016-06-21
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
University of Iowa
Phase 1 Completed
NCT01155258 2016-06-13
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
University of Southern California
Phase 1 Completed
NCT01152827 2015-05-20
PheoCarcRAD001
Seoul National University Hospital
Phase 2 Completed
NCT01959711 2013-10-10
Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy
Jagiellonian University
Phase 4 Completed
NCT00466856 2012-05-18
Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated